newsfilter
← Latest News
GlobeNewswire·

Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ:ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule